GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Divi's Laboratories Ltd (NSE:DIVISLAB) » Definitions » Cyclically Adjusted PS Ratio

Divi's Laboratories (NSE:DIVISLAB) Cyclically Adjusted PS Ratio : 21.38 (As of Jun. 05, 2025)


View and export this data going back to 2003. Start your Free Trial

What is Divi's Laboratories Cyclically Adjusted PS Ratio?

As of today (2025-06-05), Divi's Laboratories's current share price is ₹6628.50. Divi's Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was ₹310.00. Divi's Laboratories's Cyclically Adjusted PS Ratio for today is 21.38.

The historical rank and industry rank for Divi's Laboratories's Cyclically Adjusted PS Ratio or its related term are showing as below:

NSE:DIVISLAB' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 17.69   Med: 18.76   Max: 21.33
Current: 21.33

During the past years, Divi's Laboratories's highest Cyclically Adjusted PS Ratio was 21.33. The lowest was 17.69. And the median was 18.76.

NSE:DIVISLAB's Cyclically Adjusted PS Ratio is ranked worse than
97.7% of 738 companies
in the Drug Manufacturers industry
Industry Median: 2.155 vs NSE:DIVISLAB: 21.33

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Divi's Laboratories's adjusted revenue per share data for the three months ended in Mar. 2025 was ₹97.340. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ₹310.00 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Divi's Laboratories Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Divi's Laboratories's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Divi's Laboratories Cyclically Adjusted PS Ratio Chart

Divi's Laboratories Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 18.63

Divi's Laboratories Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 19.76 18.63

Competitive Comparison of Divi's Laboratories's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Divi's Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Divi's Laboratories's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Divi's Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Divi's Laboratories's Cyclically Adjusted PS Ratio falls into.


;
;

Divi's Laboratories Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Divi's Laboratories's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=6628.50/310.00
=21.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Divi's Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Divi's Laboratories's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=97.34/157.5517*157.5517
=97.340

Current CPI (Mar. 2025) = 157.5517.

Divi's Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200703 0.000 48.581 0.000
200803 0.000 52.407 0.000
200903 0.000 56.615 0.000
201003 0.000 65.030 0.000
201103 0.000 70.768 0.000
201203 0.000 76.889 0.000
201303 0.000 85.687 0.000
201403 0.000 91.425 0.000
201503 0.000 97.163 0.000
201603 0.000 102.518 0.000
201703 0.000 105.196 0.000
201803 0.000 109.786 0.000
201806 37.479 111.317 53.046
201809 49.878 115.142 68.249
201812 51.237 115.142 70.109
201903 42.361 118.202 56.463
201906 43.794 120.880 57.080
201909 54.455 123.175 69.653
201912 52.609 126.235 65.660
202003 48.456 124.705 61.219
202006 65.201 127.000 80.886
202009 65.886 130.118 79.777
202012 64.100 130.889 77.157
202103 63.163 131.771 75.521
202106 73.870 134.084 86.799
202109 74.852 135.847 86.811
202112 93.928 138.161 107.111
202203 88.810 138.822 100.792
202206 84.932 142.347 94.004
202209 69.986 144.661 76.222
202212 64.524 145.763 69.743
202303 69.536 146.865 74.596
202306 66.975 150.280 70.216
202309 71.917 151.492 74.794
202312 69.951 152.924 72.068
202403 86.649 153.035 89.207
202406 79.794 155.789 80.697
202409 88.019 157.882 87.835
202412 87.406 158.323 86.980
202503 97.340 157.552 97.340

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Divi's Laboratories  (NSE:DIVISLAB) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Divi's Laboratories Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Divi's Laboratories's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Divi's Laboratories Business Description

Traded in Other Exchanges
Address
Cyber Hills, Divi Towers, 1-72/23(P)/DIVIS/303, Gachibowli, Hyderabad, TG, IND, 500032
Divi's Laboratories Ltd is a specialty and generic drug manufacturing company. It is engaged in the manufacture of Active Pharmaceutical ingredients (API), Intermediates, and Nutraceutical ingredients with a predominance in exports. It also through its custom synthesis, supports pharma companies for their patented products business from gram scale requirements for clinical trials to launch as well as late life cycle management. Geographically, the company derives a majority of its revenue through exports to countries like the United States of America, Switzerland, and other countries.

Divi's Laboratories Headlines

No Headlines